Race Oncology Ltd. (RAC) Price & Analysis

Compare

31 Followers

RAC Stock Chart & Stats

AU$2.70

-AU$0.03(-2.27%)

At close: Jan 09 4:00 PM EST

AU$2.70

-AU$0.03(-2.27%)

Day’s Range― - ―

52-Week RangeAU$0.92 - AU$4.90

Previous CloseN/A

Volume68.10K

Average Volume (3M)373.28K

Market Cap

AU$421.60M

Enterprise ValueAU$400.66M

Total Cash (Recent Filing)AU$20.94M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta0.56

Next Earnings

Aug 21, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.02

Shares Outstanding181,723,920

10 Day Avg. Volume310,625

30 Day Avg. Volume373,283

Financial Highlights & Ratios

PEG Ratio0.63

Price to Book (P/B)12.69

Price to Sales (P/S)33.63

P/FCF Ratio-44.42

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.04

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Zero Debt / Low LeverageA zero-debt capital structure substantially reduces refinancing and interest-rate risk, giving Race durable financial flexibility to fund clinical programs. Over the next 2–6 months this lowers solvency pressure relative to leveraged peers and extends strategic optionality while pursuing partnerships or funding.

Strong FY2025 Gross MarginA very strong FY2025 gross margin implies favorable unit economics for the core program, meaning additional revenue can translate efficiently into gross profit. Structurally, this supports operating leverage potential if top-line stabilizes and fixed costs are managed, improving long-term profitability prospects.

Narrowing Losses / Improved BurnThe narrowing of losses and reduced cash burn in FY2025 versus FY2024 demonstrates management progress in cost control and operational discipline. If this trend continues, it meaningfully lowers near-term financing needs and increases runway to advance clinical milestones without immediate dilutive capital raises.

Bears Say

Persistent Negative Cash FlowConsistent negative operating and free cash flow means losses are translating into real cash outflows, creating ongoing funding needs. Over 2–6 months this sustains reliance on external financing or partnerships, raising dilution and limiting capacity to scale R&D or commercial activities without new capital.

Volatile And Declining RevenueA sharp FY2025 revenue decline after prior growth signals uneven commercialization and weak demand visibility. Structurally, revenue volatility undermines planning for production, trials, and go-to-market investment and increases execution risk for achieving sustainable scale absent clearer commercial traction.

Continued Losses, Declining EquityOngoing net losses and declining equity erode balance-sheet strength over time and reflect negative returns on invested capital. Persisting this pattern increases probability of further capital raises, investor dilution, or constrained strategic options unless the company achieves a sustained profitability or transformative milestone.

Race Oncology Ltd. News

Racura Oncology to List 22,554 New Shares on ASX

The latest announcement is out from Race Oncology Ltd. ( ($AU:RAC) ). Racura Oncology Ltd has applied for...

7d ago

RAC

Racura Oncology to Showcase Bisantrene Strategy at Investor R&D Symposium

An announcement from Race Oncology Ltd. ( ($AU:RAC) ) is now available. Racura Oncology has invited investors to...

8d ago

RAC

Racura Oncology Plans Investor Briefings in Hong Kong and Singapore

Race Oncology Ltd. ( ($AU:RAC) ) has issued an update. Racura Oncology has scheduled investor lunch briefings in...

9d ago

RAC

Racura Oncology Swings to Loss but Lifts Asset Backing in H1 FY26

Race Oncology Ltd. ( ($AU:RAC) ) has shared an announcement. Racura Oncology Limited reported a sharp reversal in...

13d ago

RAC

Racura fast-tracks RC220 cardioprotection data with novel blood test in CPACS trial

Race Oncology Ltd. ( ($AU:RAC) ) has provided an update. Racura Oncology has developed a new blood-based molecular...

29d ago

RAC

Racura Oncology Launches Selective Share Buy-Back Program

The latest announcement is out from Race Oncology Ltd. ( ($AU:RAC) ). Racura Oncology Ltd has notified the...

1M ago

RAC

Racura Moves to Correct Capital Structure After Option Exercise Error

Race Oncology Ltd. ( ($AU:RAC) ) has issued an update. Racura Oncology has disclosed that a November 2025...

1M ago

RAC

Racura Oncology Seeks ASX Quotation for 23,047 New Ordinary Shares

An update from Race Oncology Ltd. ( ($AU:RAC) ) is now available. Racura Oncology Ltd has applied to...

1M ago

RAC

Racura Oncology Seeks ASX Quotation for 141,645 New Shares

Race Oncology Ltd. ( ($AU:RAC) ) has provided an update. Racura Oncology Ltd has applied to the ASX...

1M ago

RAC

Racura Oncology Secures Key Bisantrene Patent Filings, Expands RC220 Clinical Programs and Bolsters Cash Position

An announcement from Race Oncology Ltd. ( ($AU:RAC) ) is now available. Racura Oncology reported a strong quarter...

1M ago

RAC

RAC FAQ

What was Race Oncology Ltd.’s price range in the past 12 months?

Race Oncology Ltd. lowest share price was AU$0.92 and its highest was AU$4.90 in the past 12 months.

What is Race Oncology Ltd.’s market cap?

Race Oncology Ltd.’s market cap is AU$421.60M.

When is Race Oncology Ltd.’s upcoming earnings report date?

Race Oncology Ltd.’s upcoming earnings report date is Aug 21, 2026 which is in 163 days.

How were Race Oncology Ltd.’s earnings last quarter?

Race Oncology Ltd. released its earnings results on Mar 03, 2026. The company reported -AU$0.023 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.023.

Is Race Oncology Ltd. overvalued?

According to Wall Street analysts Race Oncology Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Race Oncology Ltd. pay dividends?

Race Oncology Ltd. does not currently pay dividends.

What is Race Oncology Ltd.’s EPS estimate?

Race Oncology Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Race Oncology Ltd. have?

Race Oncology Ltd. has 181,723,920 shares outstanding.

What happened to Race Oncology Ltd.’s price movement after its last earnings report?

Race Oncology Ltd. reported an EPS of -AU$0.023 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.054%.

Which hedge fund is a major shareholder of Race Oncology Ltd.?

Currently, no hedge funds are holding shares in AU:RAC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Race Oncology Ltd. Stock Smart Score

Outperform

Fundamentals

Return on Equity

-47.44%

Trailing 12-Months

Asset Growth

14.28%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Race Oncology Ltd.

Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein to treat for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which is in Phase II/III clinical trial. It has a preclinical research program with the University of Newcastle for investigating Zantrene; and strategic collaboration with the University of Wollongong to evaluate Zantrene formulations. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.